Novo Nordisk (NOVOB DC) to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity
- Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved
- Wegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular risk
- Data on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues
Context
Novo Nordisk's presentation of new data on Wegovy at the European Congress on Obesity highlights promising developments in obesity treatment that could significantly impact both their market position and the industry at large. The focus on sustained weight loss and its role in menopause management suggests potential for expanded usage and new market opportunities, which might attract investor interest and influence stock performance.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#EUROPE#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES